Most deaths from urinary bladder cancer are owing to metastatic disease. A reduction in Rho GDP Dissociation Inhibitor 2 (RhoGDI2) protein has been associated with increased risk of metastasis in patients with locally advanced bladder cancer, whereas in animal models, RhoGDI2 reconstitution in cells without expression results in lung metastasis suppression. Recently, we noted an inverse correlation between tumor RhoGDI2 and Neuromedin U (NMU) expression, suggesting that NMU might be a target of the lung metastasis suppressor effect of RhoGDI2. Here we evaluated whether NMU is regulated by RhoGDI2 and is functionally important in tumor progression. We used small interfering RNA knockdown of endogenous RhoGDI2 in poorly tumorigenic and nonmetastatic human bladder cancer T24 cells and observed increased NMU RNA expression. Although NMU overexpression did not increase the monolayer growth of T24 or related T24T poorly metastatic human bladder cancer cells, it did augment anchorage-independent growth for the latter. Overexpression of NMU in T24 and T24T cells significantly promoted tumor formation of both cell lines in nude mice, but did not alter the growth rate of established tumors. Furthermore, NMU-overexpressing xenografts were associated with lower animal body weight than control tumors, indicating a possible role of NMU in cancer cachexia. NMU overexpression in T24T cells significantly enhanced their lung metastatic ability. Bioluminescent in vivo imaging revealed that lung metastases in T24T grew faster than the same tumors in the subcutaneous microenvironment. In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer.
Introduction
Carcinoma of the bladder is the fifth most common cancer in the United States with an estimated 53 000 new cases diagnosed each year. Despite successful treatment of the primary lesion, approximately half of the patients with muscle-invasive cancers eventually develop lung metastases, leading to an estimated 12 710 deaths (Jemal et al., 2003) in the United States in 2004. The molecular basis for the development of pulmonary metastases is not well understood, but is likely to involve the progressive loss of suppressor genes and dominant gain-of-function mutations in other genes (Fidler and Ellis, 1994; Cameron et al., 2000; Steeg, 2003; Im et al., 2004; Robinson et al., 2004; Welch, 2004) .
Rho proteins regulate cell morphology and the actin cytoskeleton, and are involved in cell motility and metastasis of cancer cells (Sahai and Marshall, 2002; Oxford and Theodorescu, 2003) . RhoGTPase activities are modulated through the guanosine triphosphate-(GTP) and guanosine diphosphate-(GDP)-bound cycles. Important regulators are the Rho-GDP Dissociation Inhibitors (RhoGDIs), which sequester GDPbound Rho proteins in the cytoplasm. We have used the human bladder cell line T24 that does not produce significant lung metastasis when injected intravenously, and T24T, a T24-related line that does form lung metastases Seraj et al., 2000) , to identify the GDP dissociation inhibitor 2 (RhoGDI2) as a metastasis suppressor gene . We have also found that reduced expression of RhoGDI2 protein in bladder cancers is associated with decreased survival for patients following radical treatment (Theodorescu et al., 2004) .
To determine how RhoGDI2 might suppress metastasis, we carried out a DNA microarray analysis comparing RhoGDI2 reconstituted T24T and vector control cells, and noted that levels of Neuromedin U (NMU) were significantly reduced (Titus et al., 2005) . Human NMU is synthesized as a 174-amino-acid precursor protein, undergoing C-terminal cleavage into a mature peptide of 25 amino acids. This peptide is found at highest levels in the gut and genitourinary system, and two receptors for it (NMUR1 and NMUR2) are preferentially expressed in either peripheral or central nervous system tissues (Brighton et al., 2004) . NMU was initially characterized as causing smooth muscle contraction and increasing blood pressure and was also shown to regulate body weight, having an anorexigenic effect independent of the leptin signaling pathway (Hanada et al., 2004) . Although no connection between NMU expression and tumor cachexia (Tisdale, 2005 ) has yet been documented, such a link would be clinically important, as the design of small molecule inhibitors of NMU receptors is feasible. With regard to tumorigenesis, NMU has been shown to be downregulated in oral tumors (Alevizos et al., 2001) , identified as an ovarian cancer-associated antigen (Euer et al., 2005) , and acts as a potential autocrine growth factor for human myeloid leukemias (Shetzline et al., 2004) .
In this study, we sought to determine whether NMU is causally related to tumor formation and lung metastasis of bladder cancer cells, and a target of the metastasis suppressor RhoGDI2. Furthermore, as NMU had been shown to be involved in weight control, we examined whether tumors overexpressing NMU were more significantly associated with cancer cachexia than those without such expression. Given that receptors for NMU are similar in structure to those for endothelin 1 (ET-1) and an endothelin receptor-specific antagonist such as atrasentan is currently in clinical use (Nelson et al., 2003) , our findings might lead to novel therapeutic approaches to reduce tumor growth, metastasis and cancer-induced weight loss by targeting this molecule.
Results

Expression of NMU is regulated by RhoGDI2
Previous data showed that RhoGDI2 is more highly expressed in the non-metastatic T24 cells compared to the lung metastatic variant, T24T . Following stable re-expression of RhoGDI2 in T24T, these cells lose their lung metastatic potential and this is associated with a decreased expression of several genes including NMU (Titus et al., 2005) . We sought to determine if NMU downregulation was causally linked to RhoGDI2 expression or merely an epiphenomenon of transfection and selection of stable clones. If the former were indeed the case, then NMU might be a functionally important downstream target of RhoGDI2. Using real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis, we confirmed that the expression of NMU was higher in RhoGDI2-deficient T24T and T24T-pcDNA cell lines, but lower in T24 and re-constituted T24T-RhoGDI2 cell lines. The expression of NMU decreased 4.5-fold in T24T-RhoGDI2 cells compared to T24T-pcDNA cells and 3.5-fold in T24 cells versus T24T cells (Figure 1a) .
To investigate the role of endogenous RhoGDI2 in regulating the level of NMU, we transiently transfected T24 cells with two RhoGDI2-specific small interfering RNA (siRNA) oligonucleotides RhoGDI2-A and RhoGDI2-B, and examined their effect on the endogenous mRNA level of NMU. Real-time RT-PCR analysis confirmed reduction of RhoGDI2 mRNA level for both RhoGDI2-specific siRNA oligonucleotides (Figure 1b ), which were paralleled by the Western blot analysis (Figure 1b, inset) . Importantly, both knockdowns of RhoGDI2 resulted in a significant increase in the expression of the endogenous NMU in T24 cells compared with the luciferase knockdown control (Figure 1b) . The increase of NMU expression ranged from 1.4-to 2.8-fold. These data clearly indicate that the RhoGDI2 protein can act as a modulator NMU expression in T24 bladder cancer cells.
Generation of NMU-overexpressing human bladder cell lines
To study the effect of NMU overexpression on tumor formation, we transfected pIRES-NMU and pIRES plasmids into the non-tumorigenic T24 bladder cancer cells and randomly selected two pIRES-NMU-transfected and puromycin-resistant cell clones (T24-NMU1 and T24-NMU2) and a vector control cell pool (T24-pIRES). High NMU mRNA level was confirmed by real-time PCR (data not shown). The NMU expression in NMU-transfected T24 cells was approximately 120-fold compared with the control T24-pIRES cell pool. In order to evaluate the effect of NMU overexpression on lung metastasis formation, we used a similar strategy and co-transfected pIRES-NMU or pIRES with the firefly luciferase plasmid into the T24T cells. We randomly selected two luciferase-labeled clones T24T-NMU-luc and T24T-pIRES-luc, and two non-luciferaselabeled clones T24T-NMU and T24T-pIRES (data not shown). The NMU expression in T24T-NMU-luc-and T24T-NMU-stable clones increased B40-fold compared with their control T24T-pIRES cell clones. The two luciferase-labeled clones T24T-NMU-luc and T24T-pIRES-luc had similar luciferase activities, which were 64 624 and 71 554 a.u./10 4 cells, respectively.
NMU overexpression does not affect monolayer growth but promotes anchorage-independent growth in T24T cells To evaluate the monolayer growth of vector control and NMU-overexpressing T24 and T24T cell lines, 10 4 cells of each were inoculated in each well of 24-well plates and used to generate growth curves. As shown in Figure 1c , monolayer growth from two NMU stably expressed T24 cell clones was slower than that for its vector control cells (P ¼ 0.003 for T24-NMU1 and P ¼ 0.002 for T24-NMU2 cells). This finding was reproducible in three independent experiments. In contrast, NMU overexpression did not significantly change the cell growth in T24T cells in three independent experiments (Figure 1d ). When anchorageindependent growth (clonogenicity in soft agar) was evaluated, we observed that two NMU-overexpressing T24T cell clones T24T-NMU and T24T-NMU-luc had more colonies at 13 days of culture than their control clones T24T-pIRES and T24T-pIRES-luc (Figure 1e ). When AlphaEaseFC software was used to quantify the colony density, there were statistically significant differences in T24T-NMU versus T24T-pIRES, or T24T-NMU-luc versus T24T-pIRES-luc cells (Figure 1f ).
No colony formation was seen in T24-NMU1, T24-NMU2 or T24-pIRES cells, as in parental T24 cells. Thus, high level of NMU expression promoted cell anchorage-independent growth in T24T cells but not in T24 cells. 4 cells/well were plated in 24-well plates and examined at various times; cell numbers were estimated using Alamar Blue assay. Fluorescence emission was assessed on the designated day from plating. Mean was obtained from quadruplicate samples. (d) Growth curves were obtained from monolayer culture of T24T-NMU-luc, T24T-NMU, T24T-pIRES-luc and T24T-pIRES cells as for T24 above. (e and f) Anchorage-independent growth for T24T-NMU, T24T-NMU-luc, T24T-pIRES and T24T-pIRES-luc cell lines. Colony formation in agar was carried out in 0.4% agar/media containing 5% serum for 13 days and quantified as described in Materials and methods. Arrow indicates typical scored colony. AlphaEaseFC software was used to quantify the colony density. There were statistically significantly differences in T24T-NMU versus T24T-pIRES (*P ¼ 0.047) and T24T-NMUluc versus T24T-pIRES-luc cells (*P ¼ 0.04). Error bars are described in Materials and methods section.
NMU promotes in vivo tumorigenicity and tumor-induced cachexia in mice harboring bladder cancer xenografts To investigate whether NMU has a role in tumor development in vivo, we injected 10 6 T24 stably transfected with NMU subcutaneously into the right and left flanks of athymic nude mice. At 6-11 weeks after an injection, the tumor incidence in the mice receiving injections of T24-NMU stably transfected cells, was significantly higher than that of mice receiving injections of vector control stable cells (Figure 2a ). Interestingly, although NMU transfection resulted in a decrease in monolayer growth for T24 cells, NMUoverexpressing T24 cells demonstrated more tumorigenicity in mice, suggesting a role for NMU in the tumor microenvironment.
In view of the role of NMU in body mass control, we examined whether NMU overexpression may have importance in cancer-induced cachexia. By examining mouse body weight after subtraction of tumor weight we found that mice harboring the NMU-overexpressing tumors had significantly (P ¼ 0.037) lower weight than mice harboring vector control-transfected xenografts both as a function of time following injection ( Figure 2b ) and as a function of xenograft size (Figure 2c) .
Using caliper measurement, seven of 10 injection sites receiving luciferase-labeled T24T-NMU-luc cells were observed to develop tumors by the third week after subcutaneous injection, whereas none of injection sites receiving luciferase-labeled T24T-pIRES-luc cells had tumors in this time period. However, using Xenogen Bioluminescent imaging at 3 weeks, eight of 10 injection sites receiving luciferase-labeled T24T-NMU-luc cells had developed tumors, and two receiving luciferaselabeled T24T-pIRES-luc cells had developed tumors (Figure 3a) indicating the superior sensitivity of the Xenogen technology compared to caliper measurements of tumor xenografts (Jenkins et al., 2003) .
To determine if the luciferase construct had any role in tumor formation, we evaluated cell lines that did not contain luciferase vector. In these cells, eight of 10 injection sites receiving T24T-NMU cells developed tumors 2 weeks after subcutaneous injection, whereas three of 10 injection sites receiving T24T-pIRES cells had tumors. These results were relatively consistent with those from luciferase-labeled cells. Overall, in addition to enhanced tumor formation, the average tumor volume was greater in NMU-overexpressing cells compared with control cells (Figure 3b) . Furthermore, an excellent correlation between caliper tumor measurement and Xenogen imaging of tumor xenograft was observed (Figure 3c ).
NMU promotes pulmonary metastasis in T24T cells
To determine if NMU promotes bladder cancer metastasis, NMU-overexpressing T24 and T24T cells were injected via tail vein in nude mice. Thirty nude mice were injected via tail vein with either 10 6 vector-or NMU-transfected cells in four distinct groups (Table 1) . At 18 weeks, animals injected with T24 derivative cells were killed, and T24-NMU2 and T24-pIRES cells did not produce metastasis, similar to untransfected T24 cells (Table 1) .
Mice injected with T24T-NMU-luc or T24T-pIRESluc were imaged using the bioluminescence scanner ( Figure 4) . As early as the third week after the T24T-NMU-luc cell injection, lung metastases were detected by bioluminescence (4a). When signals compatible with lung metastasis were noted, the findings were confirmed by magnetic resonance imaging (MRI) (Figure 4a ). Bioluminescence imaging (BLI) detected pulmonary metastases in four of five mice injected with T24T-NMU-luc cells, whereas none of the five mice injected with T24T-pIRES-luc cells had gross lung metastasis. Furthermore, when growth rates of metastatic and subcutaneous tumors generated from T24T NMUtransfected cells were compared using luciferase measurements, lung metastases grew at a significantly higher rate (Figure 4b ). 
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Mice injected with T24T-transfected cells were killed at 11 weeks as parental T24T cells begin to have metastatic pulmonary tumors B12 weeks after injection . T24T-NMU or T24T-NMU-luc cells produced significantly more metastatic tumors in the lungs compared to controls (Table 2) . No grossly apparent metastatic tumors were observed in other organs. Overall, the representative animal autopsies showed that 7/10 mice with NMU-overexpressing T24T cells developed gross lung metastases while none of the control mice did (Figure 4c) . Furthermore, all tumor growth detected by imaging was confirmed at autopsy.
Examination of the lungs using a dissecting microscope ( Â 10) revealed two abnormal nodules in 10 control animals, which were confirmed by histological sectioning of the lungs as urothelial cancer (data not shown). Representative sections of control lungs were also examined for metastases not visible with Â 10 magnification and none were found.
Discussion
Pathways involving the small GTPase Rho are important in a variety of cellular processes, such as regulation of stress fibers, cell motility, malignant transformation and metastasis. Overexpressing the RhoC protein enhances pulmonary metastasis, whereas dominantnegative RhoC inhibits it (Clark et al., 2000) . The levels of RhoA and RhoC have also been reported as predictors of metastasis for patients with bladder cancer (Kamai et al., 2003a, b) . RhoGDIs can sequester GDPbound Rho proteins in the cytoplasm to prevent Rho c Microscopic tumors are defined as those that are only visible by Â 10 dissection microscopy.
Neuromedin U enhances lung metastasis Y Wu et al from protein activation. Reduced levels of the metastasis suppressor RhoGDI2 are associated with decreased survival for patients with bladder cancer. After RhoG-DI2 reconstitution in bladder cancer T24T cells, RhoGDI2 was shown to suppress ET-1 and NMU expression. Endothelin antagonism resulted in a reduction of bladder cancer T24T lung metastasis (Titus et al., 2005) . Our study aimed at addressing whether NMU has a role in bladder cancer tumorigenicity and metastasis.
We found that NMU is a RhoGDI2-regulated gene, which occurs in several human cell lines. The signaling pathway between RhoGDI2 and NMU has not yet been elucidated, however, and there is no current evidence that RhoGDI2 protein can directly bind to any gene promoter. The fact that RhoGDI2 protein can be translocated into the nucleus upon some stimuli (Zhou et al., 2004) may be evidence that RhoGDI2 can modulate gene expression directly. It is more likely that RhoGDI2 does not bind the NMU gene promoter, but instead regulates its expression via effects on other signaling molecules.
Analysis of normal and malignant urothelium showed an association between NMU expression and tumor stage and grade. Interestingly, when we evaluated NMU-overexpressing bladder cancer cell lines for their growth in monolayer culture, no enhancement was found with NMU. Indeed, a slight decrease in T24 monolayer growth was observed. This is consistent with a report that recombinant expression of NMU inhibited the in vitro growth of esophageal squamous cell carcinoma (Yamashita et al., 2002) . In contrast, a high level of NMU resulted in an increase in anchorageindependent growth in metastatic T24T cells, but no effect on their non-metastatic counterpart T24. In other studies, patients with myeloid leukemia have been shown to have B400-fold increase in NMU expression compared with healthy individuals, and overexpression of NMU was also shown to promote colony formation for K562 cells (Shetzline et al., 2004) .
Despite the lack of effect in vitro, overexpression of NMU in T24 cells resulted in increased tumor formation in vivo. These findings suggest that the biological impact of NMU expression on tumor formation is highly related to the tumor microenvironment. This is consistent with the evidence that tumor-microenvironment (Chung et al., 2005) . NMU can also induce the release of inflammatory cytokines in T helper-2 (Th2)-type T cells, mast cells or macrophages (Johnson et al., 2004; Moriyama et al., 2005 Moriyama et al., , 2006 . These cytokine-releasing immune cells may stimulate neovascularization to promote the growth of neoplasms in humans. We found that overexpression of NMU also enhanced the ability of T24T cells to metastasize but did not have the same effect on T24 cells, suggesting that T24 cells require more than NMU to complete the metastatic cascade. Cancer cachexia, manifesting as weight loss, weakness and overall body decline, reduces the quality of life and hastens the demise of patients who suffer from it. Unfortunately, the molecular mechanisms underlying it are not well understood (Martignoni et al., 2003; Tisdale, 2005) . We found that increased NMU in the xenograft tumors were associated with cancer cachexia in mice. NMU itself has an anorexigenic effect in animals (Howard et al., 2000; Hanada et al., 2004; Shousha et al., 2006) , and transgenic overexpression of it promotes leanness in mice (Kowalski et al., 2005) . As NMU can function as a proinflammatory mediator by promoting interleukin (IL)-6 production in Th2-type T cells or macrophages (Johnson et al., 2004; Moriyama et al., 2006) and inhibition of IL-6 can partially attenuate or reverse cancer cachexia (Strassmann and Kambayashi, 1995) , this might be a mechanism underlying NMU-mediated cancer cachexia.
Two NMU receptors, NMUR1 (FM3) and NMUR2 (FM4) (Brighton et al., 2004) , have similar affinity for NMU. It is interesting to note that these two receptors can affect different pathways that may lead to cancer cachexia. For example, NMU induces early inflammatory responses mediated by NMUR1 in mast cells (Moriyama et al., 2005) . Other data have shown that NMU suppresses food intake by acting through the NMUR2 receptor in the brain, as intracerebroventricular administration of NMU markedly suppresses food intake in rats (Howard et al., 2000) . Icariin, a flavonol glycoside found in certain herbs, has recently been shown to stimulate NMUR2 (Zheng et al., 2005) , but its mechanism of action needs to be further characterized. Recently, Neuromedin S (NMS) has been identified in rat brain and has been shown to be an endogenous ligand for NMUR1 and NMUR2 (Ida et al., 2005) . In this study, intracerebroventricular injection of NMS decreased food intake in rats. Interestingly, this anorexigenic effect was more potent and persistent than that observed with the same dose of NMU. Antagonists to NMUR1 could inhibit mast cell-mediated inflammatory diseases (Moriyama et al., 2005) , whereas other drugs might be suitable to test for the reduction of cancer pain, as NMU has a pronociceptive role in mice and rats Yu et al., 2003) . It is possible that such antagonists will not only be useful in cancer cachexia but also in reducing tumor recurrence and metastasis. Combination therapies with agents directed at molecular targets such as NMU and endothelin (Titus et al., 2005) may have a role in reducing the development of metastasis following radical treatment of locally advanced tumors.
Materials and methods
Cell lines and primary tumor analysis
The T24 cell line was established from an invasive grade 3 human transitional cell bladder cancer in a female patient in 1973, and is non-tumorigenic and non-metastatic . The T24T cell line is a spontaneously occurring variant cell line of T24 Harding et al., 2002) . Both T24 and T24T cell lines were maintained in Dulbecco's modified Eagle's medium F12 (1:1) (Invitrogen, Carlsbad, CA, USA) supplemented with 5% heat-inactivated fetal bovine serum.
Plasmid constructs and transfection and derivation of stable cell lines A full-length NMU was subcloned from the full-length clone (Invitrogen clone ID 3864111) into the AflII and NotI sites of the pIRES vector (Invitrogen, CA, USA), using primers NMU-f: atgctgcgaacagagagctg and NMU-r: aatgaaccctgctgaccttctt. The identity of NMU insert was verified by DNA sequencing. Transfections of pIRES-NMU and its empty vector pIRES into T24 and T24T cells were performed by Fugene 6 (Roche, Indianapolis, IN, USA) using the manufacturer's instructions. Two days after the transfection, 2 mg/ml of puromycin (Invitrogen, CA, USA) was added to the fresh medium cultures for 3 weeks. After positive clones were picked, they were maintained in continuous selection of 2 mg/ml of puromycin, but puromycin was withdrawn 2 days before any in vitro or in vivo experiments. For in vivo imaging, T24T cells with Luciferase bioluminescent signal were generated as follows: pIRES-NMU or pIRES was co-transfected with the cytomegalovirus promoter-driven firefly luciferase gene into T24T cells in a ratio of 1:5. Luciferase activities were measured with the firefly luciferase reporter kit (Promega, Madison, WI, USA).
Real-time PCR
Total RNA was isolated using RNeasy minikit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA was reverse transcribed using the random primers of the ImPrompII kit (Promega, Madison, WI, USA). Negative control of cDNA samples was also prepared in the reverse transcription reaction without the addition of reverse transcriptase. The real-time PCR assay was conducted in iCycler IQ real-time PCR Detection System following the manufacturer's procedures (BioRad, Hercules, CA, USA). The fluorescent dye IQ SYBR Green Supermix was used in PCR reaction (BioRad, CA, USA). The sequences of the specific PCR primers were as follows (5 0 -3 0 ): NMU-f238-59RT, GGATTACAGCCTGAACAACAGC, NMU-r380-60RT, GGCTTTGGTAGCATTCCCATA; b-actin-f-RT, CCAGAT CATGTTTGAGACCTTCAAC, b-actin-r-RT: CCAGAGG CGTACAGGGATAGC.
siRNA knockdown A total of 4 Â 10 5 of T24 cells were seeded in 100 mm dishes. siRNA oligonucleotides (700 nmol/100 mm dish) transfection was conducted using Oligofectamine (Invitrogen, CA, USA). The luciferase pGL2 and two RhoGDI2-specific RhoGDI2-A (AAUGAUGAGAGUCUAAUUAAG) and RhoGDI2-B (AAUACGUUCAGCACACCUACA) siRNA oligonucleotides were ordered from Dharmacon (Lafayette, CO, USA). Two consecutive transfections were carried out in an interval of 24 h. Both protein and RNA extracts were prepared at 72 h after the first transfection. Western blotting was carried out as described previously . RhoGDI2 and a-tubulin antibody was purchased from Biosource (Camarillo, CA, USA) and EMD Biosciences (San Diego, CA, USA), respectively.
Cell proliferation assay and colony formation in agar Cell suspensions were obtained by trypsinization of monolayer cultures. Trypan blue staining was used to assess viability before plating of the cells. Various cell lines (10 4 cells) were incubated in each well of 24-well plates for growth curve. Cell culture media were changed every 2 days if 3 or more days of cell cultures were needed. Alamar Blue was diluted 1-20 in the cell culture media, and fluorescence emission was assessed at 4 h after the addition of Alamar Blue according to the manufacturer's protocol (Biosource, CA, USA), on the designated days from plating. Colorimetric evaluation of cell proliferation was performed using a Spectramax spectrophotometer (Molecular Devices, Sunnyvale, CA, USA) with 540 nm as excitation wavelength and 590 nm as emission wavelength. Colony formation in agar was carried out as described . AlphaEaseFC software (Alpha Innotech Corporation, CA, USA) was used to quantify the colony density.
Subcutaneous tumorigenicity and experimental metastasis assay Subcutaneous tumorigenicity and experimental metastasis in 6-week-old nude mice were evaluated as described previously Titus et al., 2005) . For subcutaneous tumorigenesis, 10 6 T24-transfected variant cells with 50% matrigel (BD Biosciences, San Jose, CA, USA) and T24T-transfected variant cells without matrigel were injected subcutaneously. For experimental metastasis, mice were given a lateral tail vein injection with 10 6 tumor cells suspended in 0.1 ml of phosphate-buffered saline. In both assays, mice were examined and weighed weekly. Animal body weight was calculated as total weight minus tumor weight (estimated as tumor volume in grams assuming tissue ¼ water density, 1 cm 3 ¼ 1 g). Subcutaneous tumors were measured by calipers weekly and volume calculated as described . In vivo imaging of subcutaneous tumors and lung metastases are described below. At indicated euthanasia times, the presence, number and size of metastatic deposits was evaluated and classified as 'gross' (tumors measurable by calipers) or microscopic (detected only by Â 10 dissection microscopy). Histological analysis of lungs was carried out as described (Theodorescu et al., 2004) , without the knowledge of experimental groups by the pathologist (HFF).
In vivo imaging of lung metastases Subcutaneous tumors and lung metastases were followed using BLI and MRI. The animals were anesthetized for imaging using isoflurane in oxygen (3% for induction and 1% for maintenance). For BLI, D-Luciferin Firefly, potassium salt (30 mg/ml luciferin, Biosynth International, Naperville, IL, USA) was injected into the intraperitoneal cavity at a dose of 150 mg/kg body weight approximately 10-15 min before imaging. Images were acquired in 5-min intervals using an IVIS 100 scanner (Xenogen Corp., Alameda, CA, USA). Total photon emissions from defined regions of interest within the images of each mouse were quantified using the Xenogen Igor Pro software.
Before euthanasia, animals with bioluminescent signals in the lungs were evaluated by MRI. Core body temperature and respirations were monitored with an SAII Model 1025 monitoring and gating system (Small Animal Instruments Inc., Stony Brook, NY, USA). Images were acquired on a 4.7 T Inova MR scanner (Varian, Palo Alto, CA, USA). The RF coil was a quadrature birdcage transceiver (RF Design Consulting, Newberry, FL, USA). Respiratory triggering pulses were generated using the SAII system. A spin echo, T1-weighted, multislice pulse sequence was used to acquire the MR images following administration of 0.3 mmol/kg Gd-DTPA (Magnevist; Schering AG Berlin, Germany) with TE (time-to-echo) ¼ 15 ms, TR (repetition time) ¼ 500 ms, a matrix of 128 Â 128 zero-filled to 256 Â 256, a field of view of 2.56 Â 2.56 cm, a slice thickness of 1 mm and four signal averages. Both coronal and transverse slices were acquired.
Statistical methods
Gene expression levels were transformed to the natural log scale to stabilize the variance. Standard two-tailed t-tests were used in cases of pairwise comparisons and error bars shown are 7s.e.m. Unless otherwise indicated, all means are of duplicate samples of a representative experiment repeated >2 times independently. For tumor formation and metastasis evaluations, a one-sided version of the exact method of Chan and Zhang (1999) was used to compare the percentage of animals with at least one lung metastasis with NMU groups compared to control. The null hypothesis was that the probability of at least one metastasis is the same in each group; the alternative was that the probability is greater in the NMU groups than in the control group. To compare the number of lung metastases, the same method was adapted for Poisson-distributed responses. This test was used to compare the number of metastases (total, large or small) in the NMU groups to each of the control groups.
